一种新的双甲替代物DD-70可能通过抑制循环氧化酶1对血液静止产生负面影响
Marcel Hrubša1, Alina Soloviova2, Catherine Gunaseelan1
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
Environment international
|August 29, 2025
概括
测试了双A替代品对血液的影响. 一种替代药物DD-70通过抑制循环氧化酶1具有强烈的抗血小板活性,可能会影响血液静止.
科学领域:
- 环境毒理学
- 血液学
- 职业健康问题
背景情况:
- 双是常见的工业化学品和环境污染物.
- 禁止使用双A (BPA) 导致使用具有未知的生物效应的替代品.
- 关于BPA替代品对人类健康的影响的数据有限.
研究的目的:
- 研究四种BPA替代品对人类和动物血静和红细胞的潜在负面影响.
- 评估这些化合物的急性毒性,血小板聚合和血液凝固效应.
主要方法:
- 在老鼠和人类细胞中使用乳酸脱酶试验评估红细胞毒性.
- 在全人血液中研究了血小板聚合,包括作用机制分析.
- 评估了血液凝固的参数.
主要成果:
- 所有测试化合物的红细胞毒性都很低 (TC50> 500μM).
- 通过抑制循环氧基酶1的作用,DD-70表现出强烈的抗血小板活性 (IC50=5. 0±2. 7μM).
- 高度 (≥100μM) 的测试替代品影响了血液凝固.
结论:
- 强大的抗血小板作用需要进一步研究其临床和职业健康影响.
- 这项研究强调了BPA替代品对血液静止的潜在风险,需要对人类进行暴露研究.
- 缺乏关于BPA替代品的知识是公众健康和环境的重大问题.
相关概念视频
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K


